Clinical study concerning anti-inflammatory effect of fixed dose therapy by budesonide/formoterol combination inhaler for moderate persistent asthmatics.

Clinical study concerning anti-inflammatory effect of fixed dose therapy by budesonide/formoterol combination inhaler for moderate persistent asthmatics. - anti-inflammatory effect of BUD/FM inhaler

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011853

Enrollment

Registered

2013-09-25

Start date

2010-03-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchial asthma

Interventions

Budesonide/formoterol(BUD/FM)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The asthmatics treated for at least 6 months with SFC250 2 puffs/day or BUD 800 micro-g + SLM 100 micro-g /day treatment in whom well-controlled status were maintained

Exclusion criteria

Exclusion criteria: Current smokers, those who had a smoking history (smoking index > 400) and patients with suspected COPD were excluded

Design outcomes

Primary

Measure	Time frame
FeNO, as a marker of airway inflammation	—

Secondary

Measure	Time frame
asthma control test (ACT) score, and the number of SABA use	—

Countries

Japan

Contacts

Public ContactMasayuki Hojo

National Center for Global Health and Medicine Devision of Respiratory Medicine

mhojo@hosp.ncgm.go.jp03-3202-7181

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026